Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110247 | 0.89 | MYC (0.34) | KDR | |
| SCHEMBL4110951 | 0.88 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL3842214 | 0.84 | CRHR1 (0.36) | CRHR1KDR | |
| SCHEMBL4113530 | 0.78 | MYC (0.32) | — | |
| SCHEMBL4111997 | 0.74 | CYP2C9 (0.37) | KDR | |
| SCHEMBL10195626 | 0.74 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL4105793 | 0.74 | CRHR1 (0.34) | CRHR1KDR | |
| SCHEMBL4106054 | 0.71 | — | — | |
| SCHEMBL10195623 | 0.65 | MYC (0.32) | — | |
| SCHEMBL4110252 | 0.65 | CYP2C9 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CRHR1 4372/4885KDR 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.